Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"We are delighted to bring this expanded Sculptra® offering to healthcare professionals in Europe, and yesterday's launch event was an exciting, well-attended re-introduction to Sculptra® and Galderma's larger aesthetics portfolio," said Alexandre Brennan, Global Business Unit Head, Aesthetics. "We continue to build a unique and extensive aesthetics offering at Galderma, and are proud to re-launch Sculptra® in Europe as the foundation of our portfolio alongside a range of complementary treatments to deliver impressive and long-lasting results for healthcare professionals and their patients."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
LAUSANNE, Switzerland -- Businesswire -- Galderma today announced a European re-launch of Sculptra® (injectable poly-L-lactic acid) - a collagen stimulator - with an updated administration protocol. This means that the product is ready for use more quickly following reconstitution, with increased levels of comfort for patients. Sculptra® can now be used immediately following a two-minute reconstitution and with the optional addition of lidocaine for patient comfort. Previously, healthcare professionals had to wait two hours following reconstitution to administer the product. Sculptra® now has the fastest reconstitution protocol of any injectable poly-L-lactic acid (PLLA) available in Europe, representing a significant growth opportunity for Galderma.
“Sculptra® has been my go-to tool for treating skin laxity resulting from aging and collagen loss in my patients’ skin, helping restore a youthful appearance,” said Dr. Christoph Martschin, Dermatologist, Akademikliniken, Department of Dermatology, Stockholm, and a featured speaker at the Sculptra® European re-launch virtual event. “This new reconstitution protocol for Sculptra® represents an exciting benefit as we are able to save valuable clinic time for clinicians while improving overall procedure comfort for our patients.”
Collagen provides structure and support to the skin. With facial aging, the skin’s natural collagen supply may decrease and could lead to skin laxity, wrinkles and roughness as skin quality worsens.[1,2] Sculptra® is a collagen stimulator that may help replenish lost collagen by gradually stimulating and increasing an individual’s own natural collagen production, helping restore skin quality and firmness.[2-5]
The updated protocol is based on new data from physiochemical studies,[6] as well as results from a randomized, evaluator-blinded, parallel-group, multi-center study (NCT03780244) evaluating the safety and effectiveness of two different dilutions of Sculptra®. This study demonstrated that treatment immediately following a two-minute reconstitution using the higher reconstitution volume (9 mL including lidocaine) was well tolerated, caused less pain on injection and was comparable to that of the reference group (Sculptra® 5 mL) in reducing wrinkle severity of nasolabial folds (NLF) at Week 48 (n=80). Additionally, the mean change in wrinkle assessment scale (WAS) from baseline (assessed by Blinded Evaluator) was similar in both Sculptra® study groups across 48 weeks and investigator assessed improvement using the Global Aesthetic Improvement Scale (GAIS) was > 90% in both Sculptra® study groups.
As part of this European re-launch and in line with the company’s intensified commitment to Sculptra®, Galderma held a dedicated interactive, virtual event with over 1,000 healthcare professionals to provide additional training and support related to this new administration protocol. The event also facilitated best practice sharing among physicians based on their clinical experiences.
“We are delighted to bring this expanded Sculptra® offering to healthcare professionals in Europe, and yesterday’s launch event was an exciting, well-attended re-introduction to Sculptra® and Galderma’s larger aesthetics portfolio,” said Alexandre Brennan, Global Business Unit Head, Aesthetics. “We continue to build a unique and extensive aesthetics offering at Galderma, and are proud to re-launch Sculptra® in Europe as the foundation of our portfolio alongside a range of complementary treatments to deliver impressive and long-lasting results for healthcare professionals and their patients.”
Sculptra® was first approved in Europe in 1999, in the United States in 2009 and in Brazil in 2004. Sculptra® is now available in more than 40 countries globally, and additional regulatory reviews of applications for Sculptra® in various regions are ongoing.
About Sculptra®
Sculptra® works to stimulate the skin’s own collagen production and is suitable for increasing the volume of depressed areas, particularly to correct skin depressions such as skin creases, wrinkles, folds, scars and for skin aging. Sculptra® is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).
Sculptra® is an injectable biostimulator containing microparticles of Poly-L-Lactic Acid (PLLA) which gradually revitalizes the skin’s structural foundation, providing natural-looking, long-term results for up to 25 months. Sculptra® was first approved in 1999 in Europe and it is currently available in more than 40 countries globally. To learn more about Sculptra® products, visit www.galdermaaesthetics.com
About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in approximately 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with healthcare professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
[1] Shuster S, Black MM, McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93:639-643. [2] Bohnert K et al. Plast Reconstr Surg 2019;127(4):1684-92. [3] Stein P et al. J Dermatol Sci 2015;78(1):26-33.9. [4] Goldberg D et al. Dermatol Surg 2013;39(6):915-22. [5] Vleggaar D et al. J Drugs Dermatol 2014;13 (4 suppl):s29-31. [6] Baumann K et al. J Drugs Dermatol. 2020;19(12):1199-1203.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210303006096/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Galderma
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- HL만도-카카오모빌리티 ‘자율주행 주차로봇 서비스’ 상용화 협약 체결 - 뉴스와이어
- 슈나이더 일렉트릭 코리아, 전력 중단 방지를 위한 고품질의 소규모 APC UPS 신제품 출시 - 뉴스와
- 세인트조지 의과대학, 8월 입학 지원서 접수… 한국 유학생 지원 장려 - 뉴스와이어
- 삼성물산 래미안, VR 기술로 입주 고객 AS 편리해진다 - 뉴스와이어
- 한식진흥원, 가정의 달 맞아 다채로운 프로그램 진행 - 뉴스와이어
- 청담해리슨병원, 개원 9개월 만에 척추 내시경 수술 1000례 돌파 - 뉴스와이어
- 한국체육산업개발, 오픈형 가든 페스티벌 ‘2024 로즈아워페스타’ 개최 - 뉴스와이어
- 전소미 뷰티 브랜드 글맆, 첫 팝업스토어 ‘GLYFTOPIA’ 더 현대 서울서 오픈 - 뉴스와이어
- 피치바이피치와 여행 전문가들이 만든 ‘달콤한 스위스 여행’ 상품 출시 - 뉴스와이어
- 제주삼다수, 임영웅과 함께한 두 번째 광고 ‘수질관리 편’ 공개 - 뉴스와이어